December 13th 2024
A final decision on marketing authorization is anticipated for Q1 of 2025.
[Quiz] Abdominal pain after laparoscopic nephrectomy
December 15th 2017A 46-year-old male underwent a left laparoscopic radical nephrectomy for a cT1b renal cell carcinoma. Intra-operatively, a rent in the descending mesocolon was made during bowel mobilization but was not closed. Subsequently, the patient presented to the emergency room 4 days later with complaints of sudden onset sharp abdominal pain and nausea. A non-contrast computed tomography scan was obtained. What is the diagnosis?
Guidelines update: Bladder, kidney, prostate cancer
April 18th 2017This article highlights the key points of two urologic cancer guidelines (which provide evidence-based guidance) and two consensus statements (which provide consensus recommendations by a multidisciplinary panel of experts) that have been published in the past year.
PD-1 inhibitor benefit possible even after discontinuation
February 21st 2017Persistent clinical benefit was seen among a small group of patients with metastatic renal cell carcinoma who had to discontinue therapy with the PD-1 inhibitor nivolumab (Opdivo) because of immune-related adverse events, according to a study presented at the Genitourinary Cancers Symposium in Orlando, FL.
Antibiotics may negatively impact immunotherapy outcomes
February 21st 2017Administration of broad-spectrum antibiotics in patients with metastatic renal cell carcinoma (RCC) undergoing treatment with immune checkpoint inhibitors may have a negative effect on the efficacy of the immunotherapy drugs, according to the results of a recent retrospective analysis.
Uro Pipeline: FDA committee votes in favor of nocturia treatment approval
November 1st 2016Other pipeline developments discussed in this article include the initiation of an intravesical bladder cancer study, a gel treatment for ED that has met its primary endpoint, a patent awarded for the first rechargeable implantable SNM along with some other advancements.
Oral agent improves survival in advanced RCC patients
August 1st 2016Once-daily treatment with cabozantinib (CABOMETYX), an oral tyrosine kinase inhibitor, significantly improves overall survival as well as progression-free survival and objective responses rates compared with everolimus (Afinitor) in previously treated patients with advanced renal cell carcinoma, according to final results from the phase III METEOR trial.
Sunitinib vs. everolimus: PFS, toxicity differ in study
April 4th 2016In a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
January 1st 2016Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
Study appears to refute obesity paradox in kidney cancer
December 9th 2015In this interview Mark A. Preston, MD, MPH, of Brigham and Women’s hospital sat down with Richard. R. Kerr, Urology Times content channel director, to discuss the association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. The interview was conducted during the AUA annual meeting in New Orleans.